← Leaderboards
Jonathan L. Coloff
University Of Illinois At Chicago
$4,283,694
Attributed
$5,299,596
Total exposure
5
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.6M · FY2018–25$2M$1.5M$1M$500K$0
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$5,299,596 · 5
By mechanism
R01$2,784,434 · 2
R37$1,773,268 · 1
K22$564,408 · 1
R21$177,486 · 1
Top collaborators
- Everett Stone3 shared
- Kent Hoskins1 shared
Most similar at University Of Illinois At Chicago
Same institution · by research overlap
- Arnon Lavie$5,954,044
- Jonna Frasor$7,180,888
- Hongjin Li$1,115,484
- Kent Hoskins$2,286,814
- Alessandra S Eustaquio$2,282,417
Others in their field
Other Emerging Leaders on “Tumor”
- Leonard Freedman · Leidos Biomedical Research, Inc.$360,535,780
- Lynn Briscoe · Leidos Biomedical Research, Inc.$120,794,323
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$105,180,681
- Leonard Freedmand · Leidos Biomedical Research, Inc.$78,762,245
- Connie Suders · Leidos Biomedical Research, Inc.$67,882,919
- Gautam (george) Mitra · Leidos Biomedical Research, Inc.$53,523,213
Research focus
TumorGrowthIn VivoMediatingMammary NeoplasmsMalignant Breast NeoplasmTumor MetabolismMetabolismCancer CellExperimental StudySuccessPathway InteractionsNutrientEnzymesTherapy ResistantProliferatingCellsAsparagineAsparaginaseBreast Cancer PatientAreaCancer TherapyAnabolismExtracellular
Grant awards (14)
Therapeutic enzyme depletion of L-serine for cancer treatment$605,654
R01 · FY2025 · CA
Estrogen Receptor and NFkB Crosstalk in Breast Cancer$476,982
R01 · FY2025 · CA · contact PI
Targeting Serine Auxotrophy in Luminal Breast Cancer$359,689
R37 · FY2025 · CA · contact PI
Therapeutic enzyme depletion of L-serine for cancer treatment$598,635
R01 · FY2024 · CA
Estrogen Receptor and NFkB Crosstalk in Breast Cancer$453,134
R01 · FY2024 · CA · contact PI
Targeting Serine Auxotrophy in Luminal Breast Cancer$341,706
R37 · FY2024 · CA · contact PI
SQLE and Sterols Contribute to Racial Disparity in ER+ Breast Cancer Patient Survival$177,486
R21 · FY2024 · CA · contact PI
Therapeutic enzyme depletion of L-serine for cancer treatment$650,029
R01 · FY2023 · CA
Targeting Serine Auxotrophy in Luminal Breast Cancer$352,495
R37 · FY2023 · CA · contact PI
Targeting Serine Auxotrophy in Luminal Breast Cancer$359,689
R37 · FY2022 · CA · contact PI
Targeting Serine Auxotrophy in Luminal Breast Cancer$359,689
R37 · FY2021 · CA · contact PI
Identifying Proliferation-Independent Metabolic Vulnerabilities in Cancer$188,136
K22 · FY2020 · CA · contact PI
Identifying Proliferation-Independent Metabolic Vulnerabilities in Cancer$188,136
K22 · FY2019 · CA · contact PI
Identifying Proliferation-Independent Metabolic Vulnerabilities in Cancer$188,136
K22 · FY2018 · CA · contact PI